NCT03921528 - An Active Treatment Study of SRK-015 in Patients With Type 2 or Type 3 Spinal Muscular Atrophy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 22, 2019

Primary Completion Date

January 19, 2021

Study Completion Date

February 28, 2024

Conditions

Spinal Muscular AtrophySpinal Muscular Atrophy Type 3Spinal Muscular Atrophy Type 2SMANeuromuscular DiseasesMuscular AtrophyAtrophyMuscular Atrophy, SpinalNeuromuscular Manifestations

Interventions

BIOLOGICAL

SRK-015

SRK-015 is a fully human anti-proMyostatin monoclonal antibody (mAb) of the immunoglobulin G4 (IgG4)/lambda isotype that binds to human pro/latent myostatin with high affinity. SRK-015 will be administered every 4 weeks by intravenous infusion.

Trial Locations (16)

3584

Universitair Medisch Centrum Utrecht, Utrecht

10032

Columbia University, New York

20162

ASST Grande Ospedale Metropolitano Niguarda, Milan

21287

The Johns Hopkins University, Baltimore

23507

Children's Hospital of The King's Daughters, Norfolk

27157

Wake Forest School of Medicine, Winston-Salem

46026

Hospital Universitari i Politecnic La Fe, Valencia

49503

Helen DeVos Children's Hospital, Grand Rapids

75235

Childrens Medical Center Dallas, Dallas

80045

Children's Hospital Colorado, Aurora

85016

Phoenix Children's Hospital, Phoenix

94304

Stanford University, Palo Alto

97239

Oregon Health & Science University, Portland

02115

Boston Children's Hospital, Boston

Unknown

Centro Clinico Nemo Pediatrico Policlinico A. Gemelli-Università Cattolica Sacro Cuore, Roma

Hospital Sant Joan de Déu, Barcelona

All Listed Sponsors

lead

Scholar Rock, Inc.

INDUSTRY